



Group Overview



Business Activities of CMIC Group

Contract Research Organization (CRO) Business

CMIC Co., Ltd.

Monitoring, project management, data management, statistical analysis, quality management, strategic / pharmaceutical consulting, pharmacovigilance, medical writing, post-marketing surveillance, support for clinical research, epidemiology, auditing services, education / training, etc.

Businesses involved in drug development in Asia

The following operations are undertaken in Asia: strategic / pharmaceutical consulting, clinical studies, data management, pharmacovigilance, medical writing, post-marketing clinical trials.

- CMIC Korea Co., Ltd.
- CMIC ASIA-PACIFIC, PTE. LTD. (Singapore and Taiwan)
- CMIC ASIA PACIFIC (MALAYSIA) SDN. BHD. (Malaysia)
- CMIC Asia-Pacific (Hong Kong) Limited (Hong Kong)
- CMIC ASIA-PACIFIC(PHILIPPINES), INC. (Philippines)
- CMIC ASIA-PACIFIC (AUSTRALIA) PTY LTD. (Australia)
- CMIC (Beijing) Co., Ltd. (China)
- CMIC ASIA-PACIFIC (VIETNAM) COMPANY LIMITED (Vietnam)
- CMIC DATA SCIENCE VIETNAM COMPANY LIMITED (Vietnam)
- CMIC ASIA-PACIFIC (THAILAND) LIMITED (Thailand)

CMIC Pharma Science Co., Ltd.

Toxicity tests, genotoxicity tests, safety pharmacology studies, pharmacology studies, PK / TK studies, bioanalysis, pathological examination, GMP compliance tests (biological tests), stability studies, drug storage, quality tests, release tests, bioanalysis, consulting / medical writing.

CMIC, INC.

Bioanalysis for drug development in the U.S.A. (analysis of drug concentrations in biological samples).

Hamamatsu Pharma Research, Inc.

Non-clinical pharmacology study

Contract Development and Manufacturing Organization (CDMO) Business

CMIC CMO Co., Ltd.

Manufacturing of drugs / investigational drugs (tablets, capsules, powders, fine granules / granules, ointments, creams, gels, lotions, tooth paste, external-use liquids, liniments, suppositories, injections and dry syrups), and pharmaceutical development support.

CMIC CMO Korea Co., Ltd.

Contract drug manufacturing (ointments, creams, gels, and liquids for internal use [liquid crude drugs]), support for export of drugs for Korea, and QC testing.

CMIC CMO USA Corporation


Contract cGMP manufacturing (tablets, capsules, powders, granules, and microcapsules), pharmaceutical development services, and support for supply chain establishment.

CMIC BIO Co., Ltd.

Development of biopharmaceutical drug substance manufacturing technology and contract manufacturing.

Global Locations

Expanding Business Globally



Market Solutions

CMIC Inizio Co., Ltd.

Commercial : Contract MR, Dedicated Sales Teams, Customer service reps (CSRs) , Education and Training.
Non-Commercial : Medical Affairs Consulting, Contract MSL, Nurse Educators, Training program.

OrphanPacific, Inc.

Development, manufacturing and sales of drugs, especially orphan drugs.

Site Support Solutions

CMIC HealthCare Institute Co., Ltd.

Support services primarily for medical institutions and treating, maintaining, and promoting the health of patients, such as SMO services.

Healthcare Revolution

CMIC HOLDINGS Co., Ltd.

New business development, intellectual property development, etc.

CMIC Solutions Co., Ltd.

Human resource placement and sourcing services for the pharmaceutical, medicinal, and medical industries, healthcare solutions for the general public and local governments, etc.

KNOCK ON THE DOOR Inc.

Business development centered on a platform to support patients and their families

OKEIOS Inc.

Development and sales of medical and health information services using blockchain technology

CMIC Well Co., Ltd.

Business support to promote employment of persons with disabilities.

harmo Co., Ltd.

Healthcare communication channel businesses, including electronic prescription record "harmo", vaccination management systems "harmo vaccine care," etc.

animo Co., Ltd.


Animal healthcare business support

Performance of the CMIC Group

Highlights


Net Sales

(¥millions)




Operating income and ratio of operating income

(¥millions)




Ordinary profits and ratio of ordinary profits

(¥millions)




Net profit belonging to parent company shareholders

(¥millions)




Total assets

(¥millions)



Shareholders' equity and ratio of Shareholders' equity

(¥millions)



Corporate Overview

Company name: CMIC HOLDINGS Co., Ltd.
Head office: 1-1-1 Shibaura, Minato-ku, Tokyo, Japan
Founded: 1992 (Date of establishment : March 14, 1985)
Capital: 3,087,750,000 yen
Number of employees:
(on a consolidated basis) 6,354 (as of October 1, 2023)

Board of Directors:

Kazuo Nakamura, Chairman and CEO
Keiko Oishi, President and COO
Wataru Mochizuki, Representative Director and CFO
Makoto Matsukawa, Corporate Director
Shunji Katayama, Corporate Director
Akihisa Mitake, Corporate Director
Masaru Iwasaki, External Corporate Director
Takeshi Karasawa, External Corporate Director
Gregg Lindstrom Mayer, External Corporate Director
Masaru Ota, External Corporate Director
Takanori Tobe, Audit and Supervisory Board Member
Kei Hata, External Audit and Supervisory Board Member
Hidetoshi Watanabe, External Audit and Supervisory Board Member
Eiko Hakoda, External Audit and Supervisory Board Member



History of the CMIC Group

- 1985 Foundation of CMIC Co., Ltd.
- 1992 Commenced full business as the first Contract Research Organization (CRO) in Japan.
- 1994 Commenced monitoring service business.
Four CROs, including CMIC, joined together to form the Japan CRO Association.
- 1996 Started the first Site Management Organization (SMO) business in Japan.
- 1998 CRO operations launch in Korea.
- 2000 Commenced Contract Sales Organization (CSO) business.
- 2001 Commenced human resources support business / organization development support business.
Launched CRO operations in China.
- 2002 Commenced Pharmacovigilance business.
- 2003 Commenced DTC Marketing service business.
- 2004 Commenced drug quality assurance and pharmacokinetics support businesses.
- 2005 Commenced Contract Development and Manufacturing Organization (CDMO) business.
- 2006 Established a subsidiary in Singapore.
- 2007 Launched CDMO operations in the U.S.A.
- 2011 Launched the urinary biomarker assay kit for early diagnosis of kidney diseases.
- 2012 Converted to a holding company structure via a company split. CMIC Co., Ltd. changed its name to CMIC HOLDINGS Co., Ltd.
Launched the orphan drug "Buphenyl[®]" for urea cycle disorders.
- 2013 Established a subsidiary in Malaysia.
Launched the orphan drug "Normosang[®]" for acute porphyria.
- 2014 Started the development of a manufacturing process for next-generation antibodies.
- 2015 Launched bioanalysis operations in the U.S.A.
Established a subsidiary in Hong Kong.
Obtained approval for manufacturing and marketing from Astellas Pharma Inc., and launched the medical products including orphan drugs.
- 2017 Established a subsidiary in Philippines.
- 2018 Established a subsidiary in Vietnam.
Established a subsidiary in Australia.
- 2019 Launched self-collect HPV test "SelCheck Cervical Cancer."
Completed succession of electronic prescription record "harmo" from Sony.
Established a subsidiary in Thailand.
- 2020 Started the development of manufacturing technology and contract manufacturing of biopharmaceutical drug substances.
- 2021 Established a company to expand healthcare communication channel services.
- 2022 Transferred to the Prime Market of the Tokyo Stock Exchange.
Capital and business alliance with KNOCK ON THE DOOR Inc. to build a healthcare platform tailored for individuals.
- 2023 Strategic alliance with Dai Nippon Printing Co., Ltd.
Acquired OKEIOS Inc., a company that develops personal data store platform using blockchain technology.
Acquired Hamamatsu Pharma Research, Inc., a non-clinical CRO that focus on pharmacology studies.